Neurocrine Biosciences (NBIX) Misses Q4 EPS by 54c
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $155.13 --0%
EPS Growth %: -12.4%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
CULP, KFY, NNOX, More
EPS Growth %: -12.4%
Financial Fact:
Total other income: 1.55M
Today's EPS Names:
CULP, KFY, NNOX, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $0.04, $0.54 worse than the analyst estimate of $0.58. Revenue for the quarter came in at $303.5 million versus the consensus estimate of $320 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- RBC Capital on Neurocrine Bio. (NBIX): 'We like the setup and remain buyers'
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
